Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on December 11, 2017. The filing reports a corporate governance event regarding the appointment of a senior officer. The registrant is incorporated in Delaware and maintains its principal executive offices in Vancouver, B.C., Canada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the internal promotion of Lloyd Mackenzie from Vice President, Early Stage Development and CMC, to Chief Operating Officer (COO). In this new capacity, Mr. Mackenzie serves as the Company's principal operating officer. He has been with the company since May 2008, holding various technical and operational leadership roles.
Management Commentary and Compensation
As a result of his promotion to COO, Mr. Mackenzie's annual salary has been increased to $360,000. The filing highlights his background, including 15 scientific publications, four patents, and a B.Sc. in Biochemistry from Simon Fraser University. No guidance, outlook, or specific risk factors were disclosed in this document.
Investor Verification Checklist
- Verify the effective date of Lloyd Mackenzie's appointment as COO (December 11, 2017).
- Confirm the new annual salary of $360,000 for the COO role.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains none.
- Check for any subsequent filings regarding the impact of this leadership change on operational strategy.